Medical Device Company Leisheng Medical Completes ￥10M Series A Financing

According to iyiou.com, Kunshan Leisheng Medical Technology Co., Ltd. (" Leisheng Medical") has completed its Series A round of tens of millions yuan, with participation from Jiuyo Capital and Apricot Capital. Proceeds of this round will be mainly used for the development of Leisheng Medical's high-end surgical medical equipment.

Founded in 2017, Leisheng Medical is a company that develops and provides active surgical equipment, currently focusing on radiofrequency ablation and ultrasound-based surgical instrument. The ultrasound-based surgical instrument. developed by Leisheng Medical has a long duration and high performance.

Dr. Tan Wei, the founder of Leisheng Medical, has led several innovative R&D projects of more than 20 medical product in well-known medical device groups, and put forward the concept of active surgery platform with universal broadband for the first time and put it into production.

Chen Hai Gang, the partner of Apricot Capital, said, "The products for radiofrequency ablation developed by Leisheng Medical are expected to substitute a series of the imported active surgical instruments in multiple functions including process management, safety performance, control accuracy, impedance, and temperature sensor precision."

Sun Yi, managing partner of Jiuyo Capital, said, "At present, the domestic high-end active medical device market is still dominated by imported products, and domestic manufacturers are constantly strengthening their R&D capabilities. Through innovative design and strict quality control, we believe that Leisheng Medical can provide better surgical experience for domestic doctors in the near future and more cost-effective services for people."

Jiuyo Capital has strong background resources in the fields of private equity investment institutions, public funds, wealth companies, banks, trusts, investment banks and brokerages. Jiuyo Capital is committed to building a more optimized and efficient investment industry ecosystem, and thus becomes China's most influential financial resource integration and service platform.

Founded in 2015, Apricot Capital is an investment firm focused on investing in companies in the early and growing stages of the healthcare industry, including biopharmaceuticals, life sciences, medical devices, medical services, and diagnostics. Apricot Capital consists of more than 20 professionals and consultants with experience in the healthcare industry.